

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

10/027,186 12/20/2001 Francis Lee LD0251NP 9673 7590 05/02/2003 BARRY J. MARENBERG, ESQ. MINTZ, LEVIN, COHN, FERRIS, GLOVSKY & POPEO, P.C. ONE FINANCIAL CENTER BOSTON, MA 02111					
BARRY J. MARENBERG, ESQ. MINTZ, LEVIN, COHN, FERRIS, GLOVSKY & POPEO, P.C. ONE FINANCIAL CENTER BOSTON, MA 02111 ART UNIT PAPER NUMBER 1614	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
BARRY J. MARENBERG, ESQ. MINTZ, LEVIN, COHN, FERRIS, GLOVSKY & POPEO, P.C. ONE FINANCIAL CENTER BOSTON, MA 02111 ART UNIT PAPER NUMBER 1614	10/027,186	12/20/2001	Francis Lee	Francis Lee LD0251NP	
MINTZ, LEVIN, COHN, FERRIS, GLOVSKY & POPEO, P.C. ONE FINANCIAL CENTER BOSTON, MA 02111 ART UNIT PAPER NUMBE 1614	7.	590 05/02/2003			
ONE FINANCIAL CENTER BOSTON, MA 02111 ART UNIT PAPER NUMBI 1614			EXAMINER		
ART UNIT PAPER NUMBE	ONE FINANC	IAL CENTER	OVSKY & POPEO, P.C.	GOLDBERG, JEROME D	
	BOSTON, MA 02111			ART UNIT	PAPER NUMBER
DATE MAILED: 05/02/2003				1614	R
				DATE MAILED: 05/02/2003	2)

Please find below and/or attached an Office communication concerning this application or proceeding.

	,	Application N		Applicant(s)					
4.	•	10/027,186		LEE, FRANCIS					
	Office Action Summary	Examiner		Art Unit					
		Jerome D Gold	dberg	1614					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address									
Period for Reply A SHOPTENED STATISTORY REPLODED FOR REPLY IS SET TO EVRIPE 4 MONTH/S) FROM									
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).									
Status									
1)⊠ —	Responsive to communication(s) filed on 12 N								
2a) <u></u> —	·—	is action is non							
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is									
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims									
4)🛛	4)⊠ Claim(s) <u>1-60</u> is/are pending in the application.								
	4a) Of the above claim(s) is/are withdrawn from consideration.								
5)	5) Claim(s) is/are allowed.								
6)[6) Claim(s) is/are rejected.								
7)	7) Claim(s) is/are objected to.								
	Claim(s) <u>1-60</u> are subject to restriction and/or e	election require	ment.						
	on Papers								
9) The specification is objected to by the Examiner.									
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.									
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.									
''/				ved by the Examine	31.				
If approved, corrected drawings are required in reply to this Office action. 12)☐ The oath or declaration is objected to by the Examiner.									
	nder 35 U.S.C. §§ 119 and 120								
		priority under	35 U.S.C. & 119(a)	-(d) or (f)					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:									
1. Certified copies of the priority documents have been received.									
	2. Certified copies of the priority documents have been received in Application No								
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.									
	14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) The translation of the foreign language provisional application has been received.									
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.									
Attachment(s)									
2) 🔲 Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) 3.	4) [5) [6) [(PTO-413) Paper No(atent Application (PT0					

Application/Control Number: 10/027,186

Art Unit: 1614

Claims 1-60 are drawn to methods and compositions for modulating tumor growth or metastasis in a animal employing on enhanced (synergistic) combination of a an anticancer.— A-4 compound. Applicants state on page 4, lines 24-26 that the methods of the present invention provide advantages such as greater overall efficacy, for example, in achieving synergy or avoiding antagonism..."

The anticancer agents are classified in class 514 and class 424. For example, the anticancer agent, adramycin is classified in class 514, subclass 34, taxol (paclitaxel) is in class 514, and subclass 449 while cisplatin is in class 424, subclass 649.

Applicants are, therefore required to elect a single enhanced combination of one anticancer agent with one combretastatin A-4 compound for examination on the merits.

The several inventions above are independent and distinct, each from the other, as they have acquired a separate status in the art of treating as a separate subject matter for inventive effect and require independent searches. It is noted that a reference to one enhanced combination of drug would not be a reference to another enhanced combination of the drugs under 35 U.S.C. 103. Further, the claims read on a multitude of compounds, which would require many field of searches that would be an undue burden on the Examiner. Therefore, restriction for examination purposes is proper.

Applicant is required to make a provisional election even though this requirement is traversed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jerome D. Goldberg whose telephone number is (703)

Application/Control Number: 10/027,186

Art Unit: 1614

308-4606. The examiner can normally be reached on Monday through Thursday from 9 AM to 3 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-3592 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Goldberg/LR March 26, 2003

JEROME D. GOLDBERG PRIMARY EXAMINER Page 3